Eyebright Medical Technology Beijing Co Ltd
SSE:688050
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
65.69
165.6524
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology Beijing Co Ltd
Gross Profit
Eyebright Medical Technology Beijing Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Gross Profit
¥724.3m
|
CAGR 3-Years
47%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Gross Profit
¥6.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
Gross Profit
¥1.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Gross Profit
¥3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Gross Profit
¥3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Gross Profit
¥2.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Eyebright Medical Technology Beijing Co Ltd
Glance View
Nestled in the bustling heart of Beijing, Eyebright Medical Technology Co., Ltd. stands as a beacon of innovative healthcare solutions in China. Founded with the vision of transforming patient experiences and outcomes, the company has carved a niche for itself in the ophthalmic devices sector. Eyebright's story is one of relentless pursuit of excellence, where cutting-edge technology and medical expertise converge. The company has built its reputation around developing advanced medical instruments and devices tailored specifically for eye care, addressing pressing needs in ophthalmology by enhancing diagnostic and treatment capabilities. Their products, ranging from sophisticated intraocular lenses to state-of-the-art surgical equipment, are designed to not only improve precision in surgeries but also to elevate the overall efficiency and safety of ophthalmic procedures. Eyebright Medical Technology generates its revenue through a balanced ecosystem of product sales and strategic alliances. The company leverages its robust research and development arm to continually introduce new products and update existing ones, ensuring compatibility with the latest medical standards and customer demands. Collaborating with a network of hospitals, clinics, and healthcare providers, Eyebright extends its reach across China and beyond, supplying essential ophthalmic equipment to practitioners dedicated to superior eye care. Furthermore, by maintaining strong partnerships with global optical giants, they benefit from cross-border knowledge and technology exchange, which fuels their growth trajectory. This multifaceted approach not only anchors them firmly in the healthcare landscape but also positions them advantageously in the face of ever-evolving industry challenges.
See Also
What is Eyebright Medical Technology Beijing Co Ltd's Gross Profit?
Gross Profit
724.3m
CNY
Based on the financial report for Dec 31, 2023, Eyebright Medical Technology Beijing Co Ltd's Gross Profit amounts to 724.3m CNY.
What is Eyebright Medical Technology Beijing Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
48%
Over the last year, the Gross Profit growth was 47%. The average annual Gross Profit growth rates for Eyebright Medical Technology Beijing Co Ltd have been 47% over the past three years , 48% over the past five years .
You don't have any saved screeners yet